Showing results (81-90 of 292) with videos related to
Sort By:
Pageof 30
Applied Health Economics and Health Policy|July 13, 2013
Generic medicines: solutions for a sustainable drug market?Pieter Dylst, Arnold Vulto, Brian Godman, et al.Journal of Comparative Effectiveness Research|November 19, 2013
Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EULieven Annemans, Irina Cleemput, Frank Hulstaert, et al.Orphanet Journal of Rare Diseases|April 29, 2014
Shining a light in the black box of orphan drug pricingEline Picavet, Thomas Morel, David Cassiman, et al.Pharmacy World & Science : PWS|January 12, 2007
The impact of informing psychiatric patients about their medication: a systematic reviewFranciska A M Desplenter, Steven Simoens, Gert LaekemanExpert Review of Pharmacoeconomics & Outcomes Research|October 22, 2013
Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposiumEline Picavet, David Cassiman, Wim Pinxten, et al.Plos One|March 17, 2015
Insights into European drug shortages: a survey of hospital pharmacistsKim Pauwels, Steven Simoens, Minne Casteels, et al.Frontiers in Pharmacology|March 11, 2025
What role for real-world evidence in market access of biosimilars?Steven Simoens, Catherine M Lockhart, Delphine F CourmierApplied Health Economics and Health Policy|June 21, 2011
Drugs for rare diseases: influence of orphan designation status on priceEline Picavet, Marc Dooms, David Cassiman, et al.International Journal of Clinical Pharmacy|October 8, 2011
Review of the cost-effectiveness of interventions to improve seamless care focusing on medicationSteven Simoens, Anne Spinewine, Veerle Foulon, et al.Journal of Evaluation in Clinical Practice|December 24, 2010
Discharge management for patients in Flemish psychiatric hospitalsFranciska Desplenter, Gert Laekeman, Philip Moons, et al.Pageof 30